Evaluation of the Use of a Remote Monitoring and Follow-up Option for Patients With Chronic Obstructive Pulmonary Disease (BOREAL)

N/AActive Not RecruitingNCT05759247

Assistance Publique - Hôpitaux de Paris64 enrolled

Overview

The purpose of this study is to evaluate the ability of the Bora Care remote monitoring solution to detect early acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD).

Worldwide, COPD has been increasing for 20 years with nearly 300 million patients, i.e. 4 to 10% of the adult population (7.5% in France). According to the WHO, it is now the fourth leading cause of death in the world. Acute exacerbations of COPD (worsening of symptoms requiring an increase in treatment) represent frequent events in the course of the disease and the consequences are significant for the patient in terms of vital prognosis, deterioration of respiratory function, impact on quality life and for the health system in terms of cost. Missed diagnosis and delayed treatment are associated with impaired outcomes. The prevention and early treatment of acute exacerbations of COPD therefore have a major role in the management of COPD patients and could be facilitated by telemonitoring tools. The purpose of the present study is to validate the interest of remote monitoring of various parameters (cardio-respiratory, environmental, symptom questionnaires) to predict and detect early the occurrence of acute exacerbations of COPD.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

BORA Band (wristband)DEVICE

Wristband collecting patient vital signs and activity

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with COPD defined according to the SPLF recommendations, whose level of lung function in a stable state is known (measurement less than 12 months old) * Patient with at least one of the following criteria : * Hospitalized for a COPD exacerbation at the time of enrolment in the study, and having had at least one other exacerbation in the last 12 months * Followed-up and part of the active file of the site, having had at least 2 exacerbations during the last 12 months, including one with hospitalization * COPD patient with at least 2 exacerbations in the last 12 months, including one with hospitalization * Patient having given written informed consent to participate in the study * Patient affiliated to the French social security system Exclusion Criteria * Vulnerable patient (minor, protected adult, prisoner) * Patient unable to use the BoraBand tool and without access to a caregiver * Presence of a comorbidity considered unstable or very severe by the investigator * Patient already participating in another interventional research study

Locations (1)

Pneumology Department - Hôpital Cochin

Paris, France

Outcomes

Primary Outcomes

Performance of the device for early detection of AECOPD

Sensibility and specificity of the alerts computed for all AECOPD event recorded in the study

Time frame: 12 months

Secondary Outcomes

Relation between AECOPD and measured parameters

Correlation between measured parameters and observed AECOPD events

Time frame: 12 months

Compliance

Wristband wearing duration during the follow-up period

Time frame: 12 months

Description of AECOPD

Number, duration, severity of AECOPD events observed during the study

Time frame: 12 months

Quality of Life CAT

Quality of life questionnaire CAT at baseline and after 6 and 12 months - CAT : COPD Assement Test, 8 items, range 0 (no impact of COPD) - 40 (worst impact of COPD)

Time frame: 12 months

Quality of Life EQ5D5L

Quality of life questionnaire EQ5D5L at baseline and after 6 and 12 months - EQ5S5L : five dimensions, 5 levels each, final result expressed as a 5-digit number that describes the patient's health state (worsens with increasing score)

Time frame: 12 months

Satisfaction

meCUE questionnaire after 12 months

Time frame: 12 months

Symptoms - EXASCORE questionnaire

EXASCORE questionnaire at baseline and after 6 and 12 months. EXASCORE: 2 dimensions, 8 items, range 0-32 (the highest the worst)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.